dc.contributor.author | Elisaf, Moses S. | en |
dc.contributor.author | Nakou, K. | en |
dc.contributor.author | Liamis, G. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Elisaf, Moses S. | en |
dc.creator | Nakou, K. | en |
dc.creator | Liamis, G. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:59Z | |
dc.date.available | 2018-06-22T09:52:59Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41602 | |
dc.description.abstract | Tamoxifen exhibits favorable effects on the lipid and lipoprotein profile since it decreases the total and LDL cholesterol levels as well as the Lp(a) levels. Additionally, a small increase in serum triglycerides is commonly found after tamoxifen administration. However, severe hypertriglyceridemia which can sometimes be associated with life-threatening complications is occasionally noticed. Herein, we describe a patient who developed tamoxifen-induced severe hypertriglyceridemia and pancreatitis. An analysis of the underlying pathogenetic mechanisms as well as a review of the relevant literature is also provided. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Adult | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Priority journal | en |
dc.subject | Abdominal pain | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Cisplatin | en |
dc.subject | Case report | en |
dc.subject | Gemfibrozil | en |
dc.subject | Triacylglycerol | en |
dc.subject | Amylase blood level | en |
dc.subject | Drug mechanism | en |
dc.subject | Hormonal | en |
dc.subject | Middle age | en |
dc.subject | Cholesterol | en |
dc.subject | Cholesterol blood level | en |
dc.subject | Tamoxifen | en |
dc.subject | Triacylglycerol blood level | en |
dc.subject | Lipid | en |
dc.subject | Lipoprotein | en |
dc.subject | Amylase | en |
dc.subject | Hypertriglyceridemia | en |
dc.subject | Pancreatitis | en |
dc.subject | Pethidine | en |
dc.title | Tamoxifen-induced severe hypertriglyceridemia and pancreatitis | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1023/A:1008309613082 | |
dc.description.volume | 11 | |
dc.description.issue | 8 | |
dc.description.startingpage | 1067 | |
dc.description.endingpage | 1069 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Elisaf, Moses S. [0000-0003-0505-078X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0003-0505-078X | |